The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
News|Articles|September 14, 2023
Colorcon Launches New Titanium Dioxide Free Moisture Protection Coating for Pharmaceutical Tablets
Author(s)Jill Murphy
Colorcon provides customers with Opadry complete film coating systems, which intends to help reduce complexity with delivering high-quality products and ingredients.
Advertisement
Colorcon, a company that participates in the development and supply of film coating systems, specialty excipients, and functional packaging for healthcare industries, announced on Sept. 5, 2023 the launch of a new Opadry film coating system to address the moisture management needs for pharmaceutical tablets without the use of titanium dioxide (TiO2), according to the press release.
“With uncertainty around the future of TiO2 use in pharmaceutical products marketed in the European Union, global pharmaceutical manufacturers are now formulating their products without the inclusion of TiO2,” said Annabel Bordmann, Film Coatings General Manager, in a press release. “Many pharmaceutical active ingredients are moisture sensitive and require a protective coating. This new Opadry formulation delivers the TiO2 free claim and provides functional moisture protection while upholding productivity levels and overall cost effectiveness.”
Colorcon provides customers with Opadry complete film coating systems, which intends to help reduce complexity with delivering high-quality products and ingredients.
“Moisture management is a critical aspect of pharmaceutical formulations and manufacturing, especially when it comes to tablets. Exposure of active pharmaceutical ingredients (APIs) in tablets to the environmental moisture, reduces product stability,” said Dr Ali Rajabi-Siahboomi, VP & Chief Innovation Officer, in a press release. “With Colorcon’s in-depth knowledge of materials, coating technology and regulatory needs, we have developed this new Opadry TiO2 free formulation that is specifically designed to deliver protection from environmental moisture on storage and during use by patients. The coating is easy to apply and efficient for manufacturers”.
Source:
Advertisement
Related to this article
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
The FDA has approved remibrutinib for symptomatic dermographism, the first such therapy, extending an oral BTK inhibitor label via the Phase III RemIND trial.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral
2
Manufacturing Intelligence: Organoids, Organ-on-a-Chip, and the Trust Gap
3
PharmTech AI Pulse Check: On-Prem vs. Cloud AI
4
What the Olanzapine Depot Approval Means for CMC Teams
5